Transarterial Embolization for Hepatocellular Carcinoma: A Comparison between Nonspherical PVA and MicrospheresReport as inadecuate




Transarterial Embolization for Hepatocellular Carcinoma: A Comparison between Nonspherical PVA and Microspheres - Download this document for free, or read online. Document in PDF available to download.

BioMed Research International - Volume 2015 2015, Article ID 435120, 5 pages -

Clinical Study

Radiology Division, Hospital de Clínicas de Porto Alegre HCPA, Porto Alegre, RS, Brazil

Surgery Division, Hospital de Clínicas de Porto Alegre HCPA, Porto Alegre, RS, Brazil

Institute for Health Technology Assessment, Universidade Federal do Rio Grande do Sul UFRGS, Porto Alegre, RS, Brazil

School of Medicine, Universidade Federal do Rio Grande do Sul UFRGS, Porto Alegre, RS, Brazil

Gastroenterology Division, Hospital de Clínicas de Porto Alegre HCPA, Porto Alegre, RS, Brazil

Received 4 February 2015; Revised 4 May 2015; Accepted 14 May 2015

Academic Editor: Mohammad Ahmad Al-Shatouri

Copyright © 2015 Leandro Armani Scaffaro et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Abstract

Transarterial chemoembolization TACE and transarterial embolization TAE have improved the survival rates of patients with unresectable hepatocellular carcinoma HCC; however, the optimal TACE-TAE embolic agent has not yet been identified. The aim of this study was to compare the effect of two different embolic agents such as microspheres ME and polyvinyl alcohol PVA on survival, tumor response, and complications in patients with HCC submitted to transarterial embolization TAE. Eighty HCC patients who underwent TAE between June 2008 and December 2012 at a single center were retrospectively studied. A total of 48 and 32 patients were treated with PVA and ME, respectively. There were no significant differences in survival or tumoral response between groups PVA or ME. Overall survival rates at 12, 18, 24, 36, and 48 months were 97.9, 88.8, 78.9, 53.4, and 21.4% in the PVA-TAE group and 100, 92.9, 76.6, 58.8, and 58% in the ME-TAE group . Patients submitted to TAE with ME presented postembolization syndrome more frequently when compared with the PVA group . According to our cohort, the choice of ME or PVA as embolizing agent had no significant impact on overall survival.





Author: Leandro Armani Scaffaro, Cleber Dario Pinto Kruel, Steffan Frosi Stella, Gabriela Leal Gravina, Geraldo Machado Filho, Carlos

Source: https://www.hindawi.com/



DOWNLOAD PDF




Related documents